Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation

Clinical and Experimental Metastasis

Volumn 32, Issue 5, 2015, Pages 441-455

  Ricciardelli, Carmela ^a   Lokman, Noor A ^a   Cheruvu, Sowmya ^a   Tan, Izza A ^a   Ween, Miranda P ^b   Pyragius, Carmen E ^a   Ruszkiewicz, Andrew ^c,d   Hoffmann, Peter ^b   Oehler, Martin K ^a,e  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d Royal Adelaide Hospital ^*  (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Glucose metabolism; Invasion; Metastasis; Motility; Ovarian cancer; Oxythiamine; Pentose phosphate pathway; Proliferation; Transketolase

Indexed keywords

OXYTHIAMINE; TRANSKETOLASE; MESSENGER RNA; TUMOR MARKER;

ADULT; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYSTADENOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARIAN CANCER CELL LINE; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CELL; PERITONEUM METASTASIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; AGED; APOPTOSIS; CANCER GRADING; CANCER STAGING; CELL MOTION; CYSTADENOCARCINOMA; ENZYME IMMUNOASSAY; ENZYMOLOGY; FOLLOW UP; GENETICS; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION; TUMOR RECURRENCE; TWO DIMENSIONAL GEL ELECTROPHORESIS; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYSTADENOCARCINOMA, SEROUS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; PROTEOMICS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; TRANSKETOLASE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84930576794     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-015-9718-1     Document Type: Article

References (75)

1. Jemal A et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90
2. Auersperg N et al (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22(2):255–288
3. Gardner MJ et al (1995) Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett 91(2):229–234
4. Freedman RS et al (2004) Peritoneal inflammation—a microenvironment for epithelial ovarian cancer (EOC). J Transl Med 2(1):23
5. Strobel T, Cannistra SA (1999) Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 73(3):362–367
6. Ricciardelli C, Rodgers RJ (2006) Extracellular matrix of ovarian tumors. Semin Reprod Med 24(4):270–282
7. Said NA et al (2007) SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia 9(1):23–35
8. Heyman L et al (2008) Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro. Tumour Biol 29(4):231–244
9. Kenny HA et al (2008) The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Investig 118(4):1367–1379
10. Ween MP et al (2011) Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer 128(7):1570–1584
11. Lokman NA et al (2013) Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. Oncotarget 4(8):1199–1211
12. Lindqvist Y et al (1992) Three-dimensional structure of transketolase, a thiamine diphosphate dependent enzyme, at 2.5 A resolution. EMBO J 11(7):2373–2379
13. Zhao J, Zhong CJ (2009) A review on research progress of transketolase. Neurosci Bull 25(2):94–99
14. Cascante M et al (2000) Role of thiamin (vitamin B-1) and transketolase in tumor cell proliferation. Nutr Cancer 36(2):150–154
15. Blass JP, Gibson GE (1977) Abnormality of a thiamine-requiring enzyme in patients with Wernicke–Korsakoff syndrome. N Engl J Med 297(25):1367–1370
16. Gibson GE et al (1988) Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer’s disease. Arch Neurol 45(8):836–840
17. Boros LG et al (1997) Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 57(19):4242–4248
18. Boros LG et al (2000) Transforming growth factor beta2 promotes glucose carbon incorporation into nucleic acid ribose through the nonoxidative pentose cycle in lung epithelial carcinoma cells. Cancer Res 60(5):1183–1185
19. Boros LG et al (1998) Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: a possible mechanism of antitumor action. Med Hypotheses 50(6):501–506
20. Rais B et al (1999) Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich’s tumor cells through inhibition of the pentose cycle. FEBS Lett 456(1):113–118
21. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11):891–899
22. Seyfried TN, Shelton LM (2010) Cancer as a metabolic disease. Nutr Metab 7:7
23. Warburg O (1956) On the origin of cancer cells. Science 123(3191):309–314
24. Kelloff GJ et al (2005) Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11(8):2785–2808
25. Kelloff GJ et al (2007) FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol 14(3):330–339
26. Lavayssiere R, Cabee AE, Filmont JE (2009) Positron emission tomography (PET) and breast cancer in clinical practice. Eur J Radiol 69(1):50–58
27. Wittig R, Coy JF (2008) The role of glucose metabolism and glucose-associated signalling in cancer. Perspect Med Chem 1:64–82
28. Boren J et al (2002) Metabolic control analysis aimed at the ribose synthesis pathways of tumor cells: a new strategy for antitumor drug development. Mol Biol Rep 29(1–2):7–12
29. Ramos-Montoya A et al (2006) Pentose phosphate cycle oxidative and nonoxidative balance: a new vulnerable target for overcoming drug resistance in cancer. Int J Cancer 119(12):2733–2741
30. Langbein S et al (2006) Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: warburg effect reinterpreted. Br J Cancer 94(4):578–585
31. Coy JF et al (1996) Molecular cloning of tissue-specific transcripts of a transketolase-related gene: implications for the evolution of new vertebrate genes. Genomics 32(3):309–316
32. Mitschke L et al (2010) The crystal structure of human transketolase and new insights into its mode of action. J Biol Chem 285(41):31559–31570
33. Coy JF et al (2005) Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab 51(5–6):257–273
34. Kochetov GA, Solovjeva ON (2014) Structure and functioning mechanism of transketolase. Biochim Biophys Acta 9(1844):1608–1618
35. Staiger WI et al (2006) Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep 16(4):657–661
36. Foldi M et al (2007) Transketolase protein TKTL1 overexpression: a potential biomarker and therapeutic target in breast cancer. Oncol Rep 17(4):841–845
37. Zhang S et al (2007) Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 253(1):108–114
38. Volker HU et al (2007) Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Oto-Rhino-Laryngol 264(12):1431–1436
39. Volker HU et al (2008) Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. Am J Clin Pathol 130(1):50–57
40. Langbein S et al (2008) Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer 122(11):2422–2428
41. Zhang S et al (2008) Overexpression of transketolase protein TKTL1 is associated with occurrence and progression in nasopharyngeal carcinoma: a potential therapeutic target in nasopharyngeal carcinoma. Cancer Biol Ther 7(4):517–522
42. Chen H et al (2009) Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res 28:43
43. Kayser G et al (2011) Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology 43(7):719–724
44. Grimm M et al (2013) A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer 13:569
45. Grimm M et al (2014) GLUT-1(+)/TKTL1(+) coexpression predicts poor outcome in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 117(6):743–753
46. Krockenberger M et al (2007) Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer 17(1):101–106
47. Mayer A, Von Wallbrunn A, Vaupel P (2010) Glucose metabolism of malignant cells is not regulated by transketolase-like (TKTL)-1. Int J Oncol 37(2):265–271
48. Mayer A, Von Wallbrunn A, Vaupel P (2011) Evidence against a major role for TKTL-1 in hypoxic and normoxic cancer cells. Adv Exp Med Biol 701:123–128
49. Bentz S et al (2013) Hypoxia induces the expression of transketolase-like 1 in human colorectal cancer. Digestion 88(3):182–192
50. Wanka C, Steinbach JP, Rieger J (2012) Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. J Biol Chem 287(40):33436–33446
51. Sun W et al (2010) TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res 16(3):857–866
52. Maslova AO, Meshalkina LE, Kochetov GA (2012) Computer modeling of transketolase-like protein, TKTL1, a marker of certain tumor tissues. Biochem Biokhimiia 77(3):296–299
53. Meshalkina LE et al (2013) Is transketolase-like protein, TKTL1, transketolase? Biochim Biophys Acta 1832(3):387–390
54. Schneider S et al (2012) A delta38 deletion variant of human transketolase as a model of transketolase-like protein 1 exhibits no enzymatic activity. PLoS ONE 7(10):e48321
55. Yuan W et al (2010) Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo. Cancer Biol Ther 9(9):710–716
56. Xu X et al (2009) Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer 124(6):1330–1337
57. Zhao F et al (2010) Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene 29(20):2962–2972
58. Liu H et al (2010) Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res 70(15):6368–6376
59. Shimizu T et al (2014) Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas. J Gastroenterol 49(9):1324–1332
60. Mori S et al (2009) Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 28(31):2796–2805
61. Lin CC et al (2011) Malignant pleural effusion cells show aberrant glucose metabolism gene expression. Eur Respir J 37(6):1453–1465
62. Mohd Omar MF et al (2010) Molecular-assisted immunohistochemical optimization. Acta Histochem 112(6):519–528
63. Uhlen M et al (2010) Towards a knowledge-based human protein atlas. Nat Biotechnol 28(12):1248–1250
64. Bery A et al (2014) Deciphering the ovarian cancer ascites fluid peptidome. Clin Proteomics 11(1):13
65. Paoletti F, Mocali A, Tombaccini D (1997) Cysteine proteinases are responsible for characteristic transketolase alterations in Alzheimer fibroblasts. J Cell Physiol 172(1):63–68
66. Vizan P et al (2009) Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int J Cancer 124(12):2789–2796
67. Pyragius CE et al (2013) Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer. Int J Mol Sci 14(4):7742–7756
68. Basu TK, Dickerson JW (1976) The thiamin status of early cancer patients with particular reference to those with breast and bronchial carcinomas. Oncology 33(5–6):250–252
69. Comin-Anduix B et al (2001) The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. Eur J Biochem FEBS 268(15):4177–4182
70. Pamukcu AM et al (1970) Effects of the coadministration of thiamine on the incidence of urinary bladder carcinomas in rats fed bracken fern. Cancer Res 30(11):2671–2674
71. Lu’o’ng KV, Nguyen LT (2013) The role of thiamine in cancer: possible genetic and cellular signaling mechanisms. Cancer Genomics Proteomics 10(4):169–185
72. Zhang H et al (2010) Inhibition of protein phosphorylation in MIA pancreatic cancer cells: confluence of metabolic and signaling pathways. J Proteome Res 9(2):980–989
73. Yang CM et al (2010) The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action. Clin Exp Metastasis 27(5):341–349
74. Ji H et al (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155):807–810
75. Wang J et al (2013) Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells. Exp Hematol Oncol 2:18